InsidersTradesSigma
Follow the Arcutis Biotherapeutics, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Arcutis Biotherapeutics, Inc. has logged 343 reports. Market capitalisation: €3bn. The latest transaction was filed on 8 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Welgus Howard G.. Every trade is accessible without an account.
343
Insider Decl.
n/a
Thresholds
€5m
12 ops.
Buy Volume
€26m
158 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Arcutis Biotherapeutics, Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$36.88.
42Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 16,277 of 29,064 companies
48.6
score / 100
Value33
Quality64
FCF yld-0.5%
Earn yld-0.5%
EV/EBITDA·
ROE16%
Gross mgn90%
Net mgn-4.3%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 September 2026
Declarations343 total
13,663 shares@ US$25.02620.011% mcap100.0% of flowCommonSEC144:0001628280-26-060930
11,148 shares@ US$7.510.0026% mcap5.9% of flowCommon StockSEC:0001628280-26-059444:0
11,148 shares@ US$25.02940.0088% mcap19.8% of flowCommon StockSEC:0001628280-26-059444:1
27,052 shares@ US$8.630.0074% mcap16.5% of flowCommon StockSEC:0001628280-26-059444:2
27,052 shares@ US$25.02940.021% mcap48.0% of flowCommon StockSEC:0001628280-26-059444:3
38,200 shares@ US$25.02940.030% mcap97.2% of flowCommonSEC144:0001628280-26-059254
1,072 shares@ US$7.510.0003% mcap5.8% of flowCommon StockSEC:0001628280-26-058648:0
1,072 shares@ US$26.03760.0009% mcap20.1% of flowCommon StockSEC:0001628280-26-058648:1
1,697 shares@ US$27.000.0014% mcap1.1% of flowCommon StockSEC:0001628280-26-058420:0
1,072 shares@ US$26.03760.0008% mcap100.0% of flowCommonSEC144:0001628280-26-058275
1,697 shares@ US$27.000.0014% mcap9.8% of flowCommonSEC144:0001628280-26-057973
822 shares@ US$6.52230.0002% mcap0.1% of flowCommon StockSEC:0001628280-26-058008:0
1,019 shares@ US$7.510.0002% mcap0.2% of flowCommon StockSEC:0001628280-26-058008:1
2,255 shares@ US$8.630.0006% mcap0.4% of flowCommon StockSEC:0001628280-26-058008:2
4,730 shares@ US$26.18070.0037% mcap2.8% of flowCommon StockSEC:0001628280-26-058008:3
4,730 shares@ US$26.18070.0038% mcap33.6% of flowCommonSEC144:0001628280-26-057390
8,300 shares@ US$3.640.0009% mcap0.7% of flowCommon StockSEC:0001628280-26-056898:0
8,300 shares@ US$26.52160.0068% mcap5.4% of flowCommon StockSEC:0001628280-26-056898:1
6,700 shares@ US$3.640.0007% mcap0.6% of flowCommon StockSEC:0001628280-26-056898:2
6,700 shares@ US$26.08470.0054% mcap4.3% of flowCommon StockSEC:0001628280-26-056898:3
15,000 shares@ US$26.52160.012% mcap94.1% of flowCommonSEC144:0001628280-26-055797
1,230 shares@ US$26.11680.0010% mcap1.7% of flowCommon StockSEC:0001628280-26-053754:0
4,375 shares@ US$26.11680.0035% mcap4.5% of flowCommon StockSEC:0001628280-26-053753:0
955 shares@ US$26.11680.0008% mcap0.7% of flowCommon StockSEC:0001628280-26-053755:0
955 shares@ US$26.11680.0008% mcap100.0% of flowCommonSEC144:0001628280-26-051952
25 of 343 declarations
关于 Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. 是一家在美国纳斯达克上市的美国生物制药公司，专注于医学皮肤病学和免疫皮肤病学。该公司的投资案例高度集中：它开发和商业化治疗慢性炎症性皮肤病的药物，重点是差异化的局部疗法，旨在提高疗效、安全性、耐受性和易用性，以替代更繁琐或基于类固醇的替代方案。Arcutis 成立于 2016 年，当时名为 Arcutis, Inc.，其总部位于加利福尼亚州西湖村，公司在此设有公司和运营职能部门。([arcutis.com](https://www.arcutis.com/arcutis-inc-founded-to-address-gap-in-immuno-dermatology-drug-development/?utm_source=openai)) 核心商业资产是 ZORYVE (roflumilast)，这是一种局部、选择性 PDE4 抑制剂，有多种配方和适应症。Arcutis 围绕一个涵盖斑块状银屑病、脂溢性皮炎和特应性皮炎的皮肤病学特许经营权构建其战略。2025 年，该公司获得了 FDA 批准，将 ZORYVE 乳膏 0.05% 用于 2 至 5 岁患有轻中度特应性皮炎的儿童，随后在美国推出了该产品。它还继续寻求在儿童银屑病方面的标签扩展，并生成支持该产品在常见炎症性皮肤病中表现的长期临床数据。([investors.arcutis.com](https://investors.arcutis.com/news-releases/news-release-details/fda-approves-arcutis-zoryver-roflumilast-cream-005-treatment?utm_source=openai)) 在竞争方面，Arcutis 在处方皮肤病学的一个利基但有吸引力的细分市场中运营，在该市场中，临床差异化、便利性、慢性使用耐受性和医生采纳是市场份额增长的核心。该公司将自己定位为专业公司，而非广泛的生物技术平台，拥有深厚的皮肤病学专业知识和针对经验证的炎症途径量身定制的开发引擎。这种专业化可能是一种优势，特别是如果 ZORYVE 继续在各个年龄组和适应症中扩展，但它也使业务比大型多元化同行更依赖于单一品牌特许经营权。([arcutis.com](https://www.arcutis.com/about/?utm_source=openai)) 从地理上看，Arcutis 仍然主要以美国为中心，尽管它已开始通过加拿大建立更广泛的北美业务。最近的财务更新表明，到 2025 年和 2026 年初，产品收入势头强劲，反映出 ZORYVE 特许经营权背后的商业执行加速。近期主要的催化剂包括儿科标签扩展、新产品发布、临床和长期安全性数据的持续发布，以及 2026 年持续的监管日程，以实现额外的潜在扩展。对于投资者而言，Arcutis 代表了一个具有巨大增长潜力的商业阶段专业制药公司，但它仍然面临监管时机、报销动态以及集中皮肤病学产品组合固有的执行风险。([arcutis.com](https://www.arcutis.com/arcutis-announces-first-quarter-2026-financial-results-and-provides-business-update/?utm_source=openai))
